Tofersen · Qalsody

RNA / oligonucleotide

Approvedregulatory verdict

Evidence outlook

Approved: Amyotrophic Lateral Sclerosis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
JP
  • Slowing the progression of functional impairment in patients with amyotrophic lateral sclerosis with SOD1 mutation
Product first approved 2024PMDA
EU
  • Qalsody is indicated for the treatment of adults with amyotrophic lateral sclerosis (ALS), associated with a mutation in the superoxide dismutase 1 (SOD1) gene.
Product first approved 2024EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Amyotrophic Lateral Sclerosis
NCT04856982 · Biogen
2021-05-17 – 2028-05-25 · Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
What this study did
Other / comorbidity
NCT03070119 · Biogen
2017-03-08 – 2024-08-12 · ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation
What this study did
Phase 2 (1)
Amyotrophic Lateral Sclerosis
NCT07294144 · Washington University School of Medicine
2025-12-29 – 2028-05 · ALS (Amyotrophic Lateral Sclerosis)
What this study did
Phase 1 (1)
Phase 4 (1)
Amyotrophic Lateral Sclerosis
NCT07223723 · Biogen
2025-12-11 – 2027-05-26 · Amyotrophic Lateral Sclerosis
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Amyotrophic Lateral Sclerosis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tofersen (Qalsody): this drugApprovedRNA / oligonucleotideSOD1Partial signalNo reviewed efficacy summary in this indication
Edaravone (Radicava ORS)ApprovedSmall moleculeReactive oxygen species (ROS)Weak signalFeatured results are safety only in this race
MasitinibPhase 3Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesnot yet gradedNo reviewed efficacy summary in this indication
UlefnersenPhase 3RNA / oligonucleotideFUSReliable signal
NCT04768972: FUSION (NCT04768972): ulefnersen met its primary endpoint, a joint rank (win-ratio style) analysis of time to death/permanent ventilation, time to rescue, and change in ALSFRS-R score to Day 505 vs placebo; p=0.0005.
CB03-154Phase 2/3Small moleculeKCNQ2/3 (Kv7.2/7.3) potassium channel (opener)not yet gradedNo reviewed efficacy summary in this indication
CNM-Au8Phase 2/3Nanoparticlemitochondrial energy metabolismnot yet gradedNo reviewed efficacy summary in this indication
IbudilastPhase 2/3Small moleculePDE4 and PDE10; macrophage migration inhibitory factor (MIF)not yet gradedNo reviewed efficacy summary in this indication
Tazbentetol (SPG302)Phase 2/3Small moleculeDendritic spine densityWeak signalFeatured results are safety only in this race
DazucorilantPhase 2Small moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
ForalumabPhase 2Monoclonal antibodyCD3not yet gradedNo reviewed efficacy summary in this indication
ALN-SODPhase 1/2RNA / oligonucleotideSOD1not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Qalsody (Tofersen) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
January 2027 (1)
Phase 2Amyotrophic Lateral SclerosisRecruiting
Est. primary completion 2027-01 · NCT07294144 · CT.gov ↗
What to watch
May 2027 (1)
Phase 4Amyotrophic Lateral SclerosisActive not recruiting
Est. primary completion 2027-05-26 · NCT07223723 · CT.gov ↗
What to watch
August 2027 (1)
Phase 3Amyotrophic Lateral SclerosisActive not recruiting
Est. primary completion 2027-08-07 · NCT04856982 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

October 2021Topline resultPhase 3 VALOR did not meet its primary clinical endpoint